Question · Q1 2026
Chris Parkinson sought a breakdown of the Life Sciences growth algorithm, including the effect of VP&D on price mix and momentum in tablets/cellulosics, and whether it's returning to low single-digit volume growth with constructive price mix and prior year margins for 2026/2027. He also asked about Personal Care's recovery in biofunctionals/bioactives, NPI momentum, regional demand, and growth rates excluding haircare issues for FY2026.
Answer
Guillermo Novo, Chair and CEO, noted VP&D volumes and pricing are stable. Alessandra Faccin Assis, SVP, Life Sciences and Intermediates, expects healthy growth from resilient pharma demand (low single digits) plus 200 basis points from innovate/globalize, with strong double-digit growth in injectables and tablet coatings. Guillermo Novo and Jim Minicucci, SVP, Personal Care, explained that core Personal Care is stable, with growth driven by new biofunctionals, microbial protection, and new technologies, performing well in Europe and China.
Ask follow-up questions
Fintool can predict
ASH's earnings beat/miss a week before the call
